BOK Financial’s Revance Therapeutics, Inc. RVNC Stock Holding History

BOK Financial’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,809	Closed	-$9.13K	–	1390
2024 Q4	$9.13K	Hold	2,809	–	–	﹤0.01%	979
2024 Q3	$14.8K	Buy	+2,809	New	+$14K	﹤0.01%	953

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BOK Financial's RVNC Position: Q1 2025 in Review

BOK Financial sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 2,809 shares — an estimated $9.13K sold.

BOK Financial first reported a position in RVNC in Q3 2024 and held it in 2 quarters. The position peaked at $14.8K in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

BOK Financial reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
BOK Financial sold 2,809 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $9.13K.
BOK Financial first reported a position in Revance Therapeutics, Inc. in Q3 2024 and held it in 2 quarters.
BOK Financial's Revance Therapeutics, Inc. position peaked at $14.8K in Q3 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on BOK Financial's 13F filing for Q1 2025, filed 13 May 2025.